REG - Genedrive PLC - Result of General Meeting

GenedriveAnnouncement

11/05/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230511:nRSK1355Za&default-theme=true

RNS Number : 1355Z  Genedrive PLC  11 May 2023

genedrive plc

("genedrive", the "Group" or the "Company")

 

Result of General Meeting

 

London, UK - 11 May 2023: genedrive plc (LSE: GDR), the point of care
molecular diagnostics company, announces that at the General Meeting held
earlier today, all resolutions proposed were duly passed by shareholders.

 

For information, details of the proxy voting are shown below:

 

 Resolutions  Votes For   Vote For (as % of votes cast)  Votes Against  Votes Against (as % of votes cast)  Votes Withheld
 1.           15,304,609  88.4%                          2,001,759      11.6%                               1,000
 2.           15,300,609  88.4%                          2,005,759      11.6%                               1,000
 3.           15,304,609  88.4%                          2,001,759      11.6%                               1,000
 4.           15,300,609  88.4%                          2,005,759      11.6%                               1,000

 

The full text of the resolutions can be found in the Notice of General Meeting
set out in the shareholder circular published by the Company on 24 April 2023
which is available on the Company's website www.genedriveplc.com.

 

For further information, please contact:

 

 genedrive plc                         +44 (0) 161 989 0245
 David Budd (Chief Executive Officer)
 Russ Shaw (Chief Financial Officer)

 Peel Hunt LLP - Nominated Adviser, Joint Broker                                                      +44 (0) 20 7148 8900
 James Steel / Oliver Duckworth

 finnCap Ltd - Joint Broker                          +44 (0) 20 7220 0500
 Geoff Nash / George Dollemore

 Walbrook PR - Financial PR & IR Adviser                       +44 (0) 20 7933 8780
 Paul McManus / Anna Dunphy            Or Genedrive@walbrookpr.com (mailto:Genedrive@walbrookpr.com)

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com) )

 

genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and robust point
of need molecular diagnostics platform for the diagnosis of infectious
diseases and for use in patient stratification (genotyping), pathogen
detection and other indications. The company are currently developing a
genetic test for CYP2C19 metaboliser status.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMGPUQAAUPWGUG